Terms: = Lymphoma AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF AND Treatment
17 results:
1. Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma.
Andolfo I; Lasorsa VA; Manna F; Rosato BE; Formicola D; Iolascon A; Capasso M
J Cell Mol Med; 2020 Jun; 24(11):6459-6471. PubMed ID: 32336043
[TBL] [Abstract] [Full Text] [Related]
2. Inhibition of the raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells.
Crassini K; Pyke T; Shen Y; Stevenson WS; Christopherson RI; Mulligan SP; Best OG
Leuk Lymphoma; 2018 Dec; 59(12):2917-2928. PubMed ID: 29911936
[TBL] [Abstract] [Full Text] [Related]
3. Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells.
MacDonald RJ; Bunaciu RP; Ip V; Dai D; Tran D; Varner JD; Yen A
Leuk Lymphoma; 2018 Dec; 59(12):2941-2951. PubMed ID: 29569971
[TBL] [Abstract] [Full Text] [Related]
4. Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•craf interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.
Ding H; Peterson KL; Correia C; Koh B; Schneider PA; Nowakowski GS; Kaufmann SH
Leukemia; 2017 Jul; 31(7):1593-1602. PubMed ID: 27890930
[TBL] [Abstract] [Full Text] [Related]
5. 14-3-3 proteins are essential signalling hubs for beta cell survival.
Lim GE; Piske M; Johnson JD
Diabetologia; 2013 Apr; 56(4):825-37. PubMed ID: 23354124
[TBL] [Abstract] [Full Text] [Related]
6. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.
Jin L; Tabe Y; Kimura S; Zhou Y; Kuroda J; Asou H; Inaba T; Konopleva M; Andreeff M; Miida T
Br J Cancer; 2011 Jan; 104(1):91-100. PubMed ID: 21139584
[TBL] [Abstract] [Full Text] [Related]
7. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN
Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473
[TBL] [Abstract] [Full Text] [Related]
8. Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.
Vega MI; Martínez-Paniagua M; Huerta-Yepez S; González-Bonilla C; Uematsu N; Bonavida B
Int J Oncol; 2009 Dec; 35(6):1289-96. PubMed ID: 19885551
[TBL] [Abstract] [Full Text] [Related]
9. Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.
Rao R; Lee P; Fiskus W; Yang Y; Joshi R; Wang Y; Buckley K; Balusu R; Chen J; Koul S; Joshi A; Upadhyay S; Tao J; Sotomayor E; Bhalla KN
Cancer Biol Ther; 2009 Jul; 8(13):1273-80. PubMed ID: 19440035
[TBL] [Abstract] [Full Text] [Related]
10. Overexpression of Midkine promotes the viability of BA/F3 cells.
Wang Y; Xing H; Tian Z; Tang K; Wang J; Xu Z; Rao Q; Wang M; Wang J
Biochem Biophys Res Commun; 2009 Jul; 384(3):341-6. PubMed ID: 19409372
[TBL] [Abstract] [Full Text] [Related]
11. What signals are generated by anti-CD20 antibody therapy?
Bonavida B
Curr Hematol Malig Rep; 2006 Dec; 1(4):205-13. PubMed ID: 20425315
[TBL] [Abstract] [Full Text] [Related]
12. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
Bonavida B; Vega MI
Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
[TBL] [Abstract] [Full Text] [Related]
13. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract] [Full Text] [Related]
14. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
[TBL] [Abstract] [Full Text] [Related]
15. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract] [Full Text] [Related]
16. Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, raf-1, and Src kinases.
Nimmanapalli R; O'Bryan E; Kuhn D; Yamaguchi H; Wang HG; Bhalla KN
Blood; 2003 Jul; 102(1):269-75. PubMed ID: 12623837
[TBL] [Abstract] [Full Text] [Related]
17. Trp-Lys-Tyr-Met-Val-Met activates mitogen-activated protein kinase via a PI-3 kinase-mediated pathway independent of PKC.
Baek SH; Bae YS; Seo JK; Lee YH; Kim JH; Kwun KB; Suh PG; Ryu SH
Life Sci; 1999; 65(17):1845-56. PubMed ID: 10576564
[TBL] [Abstract] [Full Text] [Related]
